Pharmaceutical Executive
Increased demand for plant-based hormones has spurred Wyeth to ask FDA to set marketing limits on compounded therapies
Pharmaceutical Executive-06-07-2006
Pharmaceutical Executive
Medicare Part D has increased drug sales and payers are still trying to hold down costs.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: FDA Approves Novo Nordisk's Rybelsus and Roche’s Gazyva/Gazyvaro
2
Merck Planning $70 Billion Investment for US Expansion
3
Amazon and WeightWatchers Partner for DTC Weight Loss Medication Offerings
4
FDA Approves Tezspire as First Biologic Targeting TSLP for Chronic Rhinosinusitis With Nasal Polyps
5
